Acute and long-lasting neurological symptoms in SARS CoV-2 infected patients.
Salazar G., Nechat C., Fragoso M., Chavarría B. i altres.
Journal of Behavioral and Brain Science 2021, març; 11(3):73-81. DOI: 10.4236/jbbs.2021.113006.
Ultrasound and electromyography as guidance tools for the botulinum toxin therapy in cervical dystonia.
Salazar G., Ferreiro S., Fragoso M., Codas J., Cruz H.
Journal of Behavioral and Brain Science 2021, feb.; 11(2):49-57. DOI: 10.4236/jbbs.2021.112004.
Post infectious Opsoclonus-Myoclonus syndrome in a Cov-2 infected patient.
Salazar G. i altres.
EC Neurology 2020; 12(9):99-101.
Guide to infiltrate botulinum toxin in neck muscles.
Salazar G.
iToxin (Teracat.com), aplicació per a Android i iOS.
Application for self evaluation in Parkinson’s disease patients.
Salazar G., Badia J.
MiParkinson, aplicació per a Android i iOS.
Rapidly progressive glomerulonephritis with anti-GBM and anti-PLA2R antibodies after Alemtuzumab treatment in a multiple sclerosis patient.
Fragoso M., Salazar G. i altres.
The Clinical Neurologist International 2019; 1(1):CNI.01-1008.
Continuous apomorphine infusion in ptients with advanced Parkinson’s disease with varying degrees of functional impairment.
Salazar G., Fragoso M., Martí J., Martín N., Bernal R.
Journal of Behavioral and Brain Science 2016, set.; 6(10):393-403. DOI: 10.1016/j.nrleng.2015.10.003.
Apomorfina en bomba de perfusión continua en pacientes con enfermedad de Parkinson avanzada con diferente grado de afectación funcional.
Salazar G., Martín J., Fragoso M., Font M.A.
Neurología 2017, jul.-ago.; 32(6):407-410. DOI: 10.1016/j.nrl.2015.10.001.
EEG findings in diffuse Lewy body disease and Parkinson’s disease with dementia.
Salazar G., Fragoso M., Español G., Estévez M., Rey A.
Brain Disorders & Therapy 2015; 4(1):156. DOI: 10.4172/2168-975X.1000156.
Effects of night-time use of rotigotine on nocturnal symptoms in Parkinson’s disease.
Vallderiola F., Compta Y., Aparicio J., Tarradellas J., Salazar G. i altres.
Parkinson’s Disease 2015; 2015:475630. DOI: 10.1155/2015/475630.
IncobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®) for chronic migraine deadache. Experience with higher doses and changes to the injection technique.
Salazar G., Fragoso M., Rey A., Sánchez L., González Navarro M.
Journal of Neurological Disorders 2014; 2(6):1000192. DOI: 10.4172/2329-6895.100019.
Lower body parkinsonism patients. Increased blood flow in posterior cerebral arteries.
Salazar G., Fragoso M., Rey A.
Austin Journal of Neurological Disorders & Epilepsy 2014; 1(2):1008.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate. The Escala Study.
Meca Lallana J.E., Balseiro J.J., Lacruz F., Guijarro C., Sánchez O., Cano A., Costa Frossard L., Salazar G. i altres.
Journal of the Neurological Sciences 2012, 15 abr.; 315(1-2):123-1288. DOI: 10.1016/j.jns.2011.11.010.
Oromandibular dystonia secondary to radiation therapy. A description of 2 cases.
Salazar G., Español G., Fragoso M.
Neurología 2014, abr.; 29(3):189-191. DOI: 10.1016/j.nrleng.2014.02.001.
Oromandibular dystonia secondary to radiotherapy. Peripheral injuries triggering thalamic disruption? A case report.
Salazar G., Español G., Fragoso M., Rey A. i altres.
Basal Ganglia 2011, nov.; 1(4):235-236. DOI: 10.1016/j.baga.2011.10.004.
